CTI BIOPHARMA CORP - FORM 10-K - EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - February 16, 2011

Attached files

file filename
10-K - FORM 10-K - CTI BIOPHARMA CORPd10k.htm
EX-32 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CTI BIOPHARMA CORPdex32.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-23.2 - CONSENT OF MARCUM LLP - CTI BIOPHARMA CORPdex232.htm
EX-23.1 - CONSENT OF STONEFIELD JOSEPHSON, INC. - CTI BIOPHARMA CORPdex231.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - CTI BIOPHARMA CORPdex211.htm
EX-10.24 - FORM OF AMENDMENT TO AMENDMENT TO EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT - CTI BIOPHARMA CORPdex1024.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm

Exhibit 12.1

RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated:

 

     Year ended December 31,  
     2010      2009      2008      2007      2006  

Ratio of earnings to fixed charges(1)

      —           —           —           —           —     

 

(1) Earnings were not sufficient to cover fixed charges for each of the periods indicated. Earnings consist of income (loss) before provision for income taxes plus fixed charges. Fixed charges consist of interest charges and that portion of rental payments under operating leases we believe to be representative of interest. Earnings for the years ended December 31, 2010, 2009, 2008, 2007 and 2006, were insufficient to cover fixed charges by $147.6, $116.8, $202.9, $148.3 and $135.8 (in millions), respectively. For this reason, no ratios are provided for these periods.

Stock widget

Investing forum

CTI BIOPHARMA CORP Reports

Also read